Core Insights - The Hong Kong Traditional Chinese Medicine (TCM) stocks showed strong performance, with China Traditional Chinese Medicine rising over 8% initially before settling at a 2.9% increase, while other stocks like Wei Yuan Tang and Tong Ren Tang Guo Yao also saw gains [1][2] Industry Developments - The Ministry of Industry and Information Technology, along with eight other departments, issued the "Implementation Plan for High-Quality Development of the TCM Industry (2026-2030)" [1] - By 2030, a collaborative development system for the entire TCM industry chain is expected to be initially formed, with enhanced stable supply capabilities for key TCM raw materials and significant improvements in digitalization and greening levels [1] - The plan emphasizes the use of artificial intelligence and big data to create knowledge graphs for classic formulas and experiences from renowned TCM practitioners [1] Policy Implications - Analysts view this plan as a systemic, long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" development [1] - The plan serves as a "general program" for the development of the TCM industry over the next five years, focusing on raising industry standards, encouraging innovation, and driving a profound supply-side reform [1]

Group 1 - The core viewpoint of the news is that the Chinese traditional medicine sector is experiencing a strong market response following the release of a new development plan by the Ministry of Industry and Information Technology and seven other departments, which aims to enhance the quality and innovation of the industry by 2030 [1] - The plan outlines that by 2030, a collaborative development system for the entire traditional Chinese medicine (TCM) industry chain will be initially formed, with a focus on stable supply of key TCM raw materials and significant improvements in digitalization and greening levels [1] - Analysts suggest that this plan represents a systematic and long-term policy benefit for TCM stocks, marking a shift from "extensive growth" to "quality and value-driven" growth, serving as a guiding framework for the development of the TCM industry over the next five years [1] Group 2 - The stock performance of TCM companies shows a positive trend, with China Traditional Chinese Medicine rising over 8% at one point, currently up by 2.9%, and other companies like Yuyuan Tang and Tong Ren Tang also experiencing gains [2] - Specific stock price changes include: Yuyuan Tang at 0.365 with a 5.80% increase, China Traditional Chinese Medicine at 2.130 with a 2.90% increase, and Fosen Pharmaceutical at 0.750 with a 1.35% increase [2] - Other companies such as Tong Ren Rong Guo Yao, Baiyun Mountain, Tong Ren Tang Technology, and Jilin Changlong Pharmaceutical also reported slight increases in their stock prices, indicating a broader positive sentiment in the TCM sector [2]

Core Viewpoint - The traditional Chinese medicine sector is experiencing active market performance, with several companies showing significant stock price increases amid broader market conditions [2] Company Performance - China Traditional Chinese Medicine (00570.HK) saw a stock price increase of 5.8%, reaching HKD 2.19 [2] - Yao Wang Tang (00897.HK) experienced a rise of 4.35%, with its stock priced at HKD 0.36 [2] - Tong Ren Tang Guo Yao (03613.HK) increased by 2.38%, trading at HKD 9.03 [2] - Tong Ren Tang Technology (01666.HK) rose by 1.83%, with a stock price of HKD 4.44 [2]

Group 1 - JD.com (SWR 89618) has the highest short-selling ratio at 85.52%, followed by AIA Group (R 81299) at 77.11% and Lenovo Group (R 80992) at 67.79% [1][2] - Tencent Holdings (00700) leads in short-selling amount with 2.709 billion yuan, followed by Pop Mart (09992) at 974 million yuan and Xiaomi Group (W 01810) at 793 million yuan [1][2] - Huatai Securities (06886) has the highest deviation value at 40.23%, followed by Tong Ren Tang Technologies (01666) at 35.46% and China Ship Leasing (03877) at 26.75% [1][2] Group 2 - The top ten short-selling ratios include JD.com at 85.52%, AIA Group at 77.11%, and Lenovo Group at 67.79% [2] - The top ten short-selling amounts show Tencent Holdings at 2.709 billion yuan, Pop Mart at 974 million yuan, and Xiaomi Group at 793 million yuan [2] - The top ten deviation values are led by Huatai Securities at 40.23%, followed by Tong Ren Tang Technologies at 35.46% and China Ship Leasing at 26.75% [2]

2.要跳出固有思维，接纳新知，拥抱变革，以"钻研精神"强本领，夯实履职根基。 3.以"实干作风"促落地，坚持学以致用、知行合一，在"保供应、拓市场、提质量"的一线攻坚中锤炼本 领、创造价值。 1月30日，北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技公司"）年度人才培养工程——"锻 造时代管理者"领导力进阶培训项目暨2026年科技公司中层干部培训班正式拉开帷幕。 来自各工商业单位、管理部室及子公司的90名中高层管理者及核心后备人才齐聚一堂，共同开启一场以 思想破冰引领行动突围、以能力升级驱动业务突破的赋能之旅。 党委副书记、总经理张春友在开班致辞中深刻剖析行业变革趋势，并对全体学员提出殷切期望。他强 调，面对战略视野、经营能力、创新思维与执行效能的全新挑战，管理者必须树立强烈的危机意识与前 瞻思维—— 1.要以"转观念、讲协调、提质效、强执行、重管理、树信心"的十八字工作方针为指引，主动应变求 变。 本次培训由同仁堂科技公司党委精心策划，将各单位及总部骨干纳入体系化赋能范围。培训项目课程紧 扣"战略管理、商业思维、营销创新、经营分析"四大核心模块、十大核心课程，精准对接中层干部履职 尽责的现实所需，聘请 ...

FF301 本月底法定/註冊股本總額： RMB 1,280,784,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | 1 | RM ...

废 机中国 PIN 4 K 苏 家 老人 家 中 DAS 游 7469x 并有 -15 Int FE 會 年 年 表 花 n | 師 mil -16 成 女 七 己 を目 花 蔵 男 き 言 版刊 九十 LI 十八 157 图 f 17 r 李青 68岁 朱德《井冈山会师》 由北京日报社北京晚报主办，北京同仁堂科技发展有限公司协办，北京书法家协会、北京同仁堂中医医 院、京报传媒大力支持的"铁血丰碑 盛世中华——第三届'墨缘杯'北京市老年书法展"入展作品揭晓。 在前两届书法展成功举办的基础上，今年参展的作品质量更胜一筹，老年书法爱好者踊跃投稿，不到两 个月的征稿时间，组委会收到了书法作品近千幅。经过专家精心评选，评出入展作品一百幅。其中楷书 16幅，篆书18幅，草书7幅，行书26幅，隶书33幅。 入展作品将于2月4日在北京同仁堂乐家老宅展厅与观众见面，欢迎读者莅临参观。 来源：北京日报客户端 ...

0 - 0 D991 時 除 It L ट P Rat 头 r , " a 199 JF t # its 95 新 元 半 六合 G artist CH382 te vi 布 通 真 美 家 系 re 125 為 精 ithe at 由北京日报社北京晚报主办，北京同仁堂科技发展有限公司协办，北京书法家协会、北京同仁堂中医医 院、京报传媒大力支持的"铁血丰碑 盛世中华——第三届'墨缘杯'北京市老年书法展"入展作品揭晓。 在前两届书法展成功举办的基础上，今年参展的作品质量更胜一筹，老年书法爱好者踊跃投稿，不到两 个月的征稿时间，组委会收到了书法作品近千幅。经过专家精心评选，评出入展作品一百幅。其中楷书 16幅，篆书18幅，草书7幅，行书26幅，隶书33幅。 入展作品将于2月4日在北京同仁堂乐家老宅展厅与观众见面，欢迎读者莅临参观。 篆书 戴宪 71岁 《书法养生》对联 来源：北京日报客户端 ...

近日，北京同仁堂科技发展股份有限公司（以下简称"北京同仁堂科技公司"）宣布与气象服务平台—— 墨迹天气达成战略合作，共同启动"感冒清热颗粒+板蓝根颗粒"冬季健康守护计划。双方将依托墨迹天 气的气象预警能力与北京同仁堂的中医药产品力，构建"天气预警+健康干预"的一体化守护体系，将传 统感冒药品升级为"家庭健康预警系统"，为用户提供更主动、更精准的健康管理服务。 据悉，本次北京同仁堂科技公司与墨迹天气的合作以墨迹天气平台为核心阵地，构建"天气预警→精准 推荐→便捷转化"的全链路健康防护闭环。北京同仁堂科技公司旗下感冒清热颗粒与板蓝根颗粒将借助 墨迹天气的海量用户覆盖与高频使用场景，在天气变化与健康风险之间建立强关联，实现从"感冒治 疗"到"健康预防"的品牌角色升级。 合作期间，用户在墨迹天气APP中通过开屏广告、首页15天预报banner、平台穿衣助手背景植入及官方 双微联动等多维触点，接触到北京同仁堂科技公司的健康防护信息，并引导用户一键跳转购药平台，实 现"即看即知即购"的便捷体验，推动从"知天气"到"护健康"的无缝衔接。 此次合作不仅是资源联动，更是理念升级。通过将中医"治未病"思想与气象大数据相结合，北京 ...

2025年以来，北京同仁堂科技发展股份有限公司（以下简称"同仁堂科技公司"）大力推动重点科研项目攻关，在新药研发、上市品种临 床研究，以及学术论文发表、行业标准制定等相关领域接连步入新阶段。企业以市场需求为导向、以科研创新为驱动的发展模式频结硕 果，老字号中药企业的核心竞争力正从传统工艺向现代科研证据体系延伸。 同仁堂科技公司聚焦上市品种的持续深耕更是成果丰硕，多项针对名优品种的临床研究步入收获期。金匮肾气丸完成了针对"肾阳虚证夜 尿频多"的临床研究，为这一经典名方治疗特定症状提供了新的临床证据。感冒清热颗粒完成了治疗普通感冒（风寒证）的有效性和安全 性临床研究，进一步明确了其适用人群和疗效特点。此外，六味地黄类方治疗糖尿病视网膜病变的药效机制研究、永盛合阿胶治疗肿瘤 相关性贫血的真实世界研究等也已完成，系统揭示了传统方药在现代疾病治疗中的科学内涵。在基础研究层面，同仁堂科技公司对加味 逍遥丸、京制牛黄解毒片等品种的药效物质基础和作用机制研究取得关键突破，致力于"讲清楚、说明白"中药为什么有效。 从衡量企业科研实力的一个重要维度——高质量论文发表来看，15篇高水平论文发表，其中3篇为SCI论文，不仅展现了公司 ...